BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Acquired Rep. Gilbert Ray Cisneros, Jr.

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). In a filing disclosed on September 04th, the Representative disclosed that they had bought between $1,001 and $15,000 in BioCryst Pharmaceuticals stock on July 10th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $15,001 – $50,000 in shares of Mesabi Trust (NYSE:MSB) on 7/31/2026.
• Purchased $1,001 – $15,000 in shares of Praxis Precision Medicines (NASDAQ:PRAX) on 7/30/2026.
• Purchased $15,001 – $50,000 in shares of Alkermes (NASDAQ:ALKS) on 7/30/2026.
• Sold $15,001 – $50,000 in shares of Crinetics Pharmaceuticals (NASDAQ:CRNX) on 7/30/2026.
• Sold $100,001 – $250,000 in shares of Alibaba Group (NYSE:BABA) on 7/24/2026.
• Sold $1,001 – $15,000 in shares of Adobe (NASDAQ:ADBE) on 7/24/2026.
• Sold $1,001 – $15,000 in shares of Viavi Solutions (NASDAQ:VIAV) on 7/21/2026.
• Purchased $1,001 – $15,000 in shares of SailPoint (NASDAQ:SAIL) on 7/21/2026.
• Purchased $1,001 – $15,000 in shares of Glacier Bancorp (NYSE:GBCI) on 7/21/2026.
• Sold $1,001 – $15,000 in shares of FedEx (NYSE:FDX) on 7/21/2026.

BioCryst Pharmaceuticals Price Performance

Shares of NASDAQ BCRX traded down $0.90 during mid-day trading on Tuesday, reaching $9.06. 9,687,047 shares of the company’s stock traded hands, compared to its average volume of 4,775,020. The business has a 50-day simple moving average of $9.75 and a 200 day simple moving average of $9.20. The stock has a market cap of $2.32 billion, a P/E ratio of -6.04 and a beta of 0.57. BioCryst Pharmaceuticals, Inc. has a 1-year low of $6.00 and a 1-year high of $11.22.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its earnings results on Wednesday, August 5th. The biotechnology company reported $0.30 earnings per share for the quarter, topping analysts’ consensus estimates of $0.15 by $0.15. The company had revenue of $218.25 million for the quarter, compared to analyst estimates of $183.28 million. BioCryst Pharmaceuticals had a negative net margin of 40.90% and a negative return on equity of 86.89%. The firm’s revenue was up 33.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.15 EPS. Equities research analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -2.25 earnings per share for the current fiscal year.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Nykredit A S bought a new position in shares of BioCryst Pharmaceuticals in the second quarter worth $27,000. Larson Financial Group LLC raised its stake in shares of BioCryst Pharmaceuticals by 1,188.0% during the 4th quarter. Larson Financial Group LLC now owns 3,542 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 3,267 shares during the period. Allworth Financial LP purchased a new stake in BioCryst Pharmaceuticals during the 2nd quarter worth about $52,000. Focus Partners Wealth purchased a new stake in BioCryst Pharmaceuticals during the 3rd quarter worth about $77,000. Finally, Envestnet Portfolio Solutions Inc. bought a new position in BioCryst Pharmaceuticals in the 4th quarter worth about $81,000. Institutional investors own 85.88% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on BCRX shares. Royal Bank Of Canada cut their target price on BioCryst Pharmaceuticals from $14.00 to $13.00 and set an “outperform” rating on the stock in a research report on Thursday, August 6th. Wedbush cut their price objective on shares of BioCryst Pharmaceuticals from $21.00 to $20.00 and set an “outperform” rating on the stock in a report on Thursday, August 6th. Cantor Fitzgerald upped their target price on shares of BioCryst Pharmaceuticals from $27.00 to $29.00 and gave the stock an “overweight” rating in a research note on Tuesday, June 30th. Needham & Company LLC reiterated a “buy” rating and issued a $16.00 target price on shares of BioCryst Pharmaceuticals in a report on Tuesday. Finally, HC Wainwright reissued a “buy” rating and set a $32.00 target price on shares of BioCryst Pharmaceuticals in a research report on Tuesday, June 30th. Eight research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $20.60.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.